NCT07444541 2026-04-16
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Phase 1/2 Not yet recruiting
Clinical Trials
69 trialsNCT07529808 2026-04-15
ChefHat-001
BigHat Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT07509008 2026-04-03
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT07504263 2026-03-31
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Recurv Pharma Inc
Phase 1/2 Not yet recruiting
NCT07477444 2026-03-20
HER-OIC
Universitaire Ziekenhuizen KU Leuven
Phase 1/2 Not yet recruiting
NCT07479485 2026-03-18
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Lepu Biopharma Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07477418 2026-03-17
PRISM-TAMP
University of Vermont
Phase 1/2 Not yet recruiting
NCT07411599 2026-03-12
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07435038 2026-03-11
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Betta Pharmaceuticals Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07456852 2026-03-09
Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07277322 2026-03-02
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Icahn School of Medicine at Mount Sinai
Phase 1/2 Not yet recruiting
NCT07435584 2026-02-27
EVER-RECODE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT07412197 2026-02-17
PREVENT-Lynch
Radboud University Medical Center
Phase 1/2 Not yet recruiting
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT07377526 2026-01-30
Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07365592 2026-01-26
Neo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT07364422 2026-01-23
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Onconic Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT07358585 2026-01-22
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
Shanghai Henlius Biotech
Phase 1/2 Not yet recruiting
NCT07357220 2026-01-21
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
Akeso
Phase 1/2 Not yet recruiting
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT07342725 2026-01-15
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Ruijin Hospital
Phase 1/2 Not yet recruiting
NCT07333573 2026-01-12
A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Not yet recruiting
NCT07282509 2025-12-15
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07269158 2025-12-08
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Phase 1/2 Not yet recruiting
NCT07263594 2025-12-04
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
DualityBio Inc.
Phase 1/2 Not yet recruiting
NCT07260058 2025-12-02
Immune Cell Therapy for Advanced Solid Tumors
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06400160 2025-11-25
Clinical Trial of TB511 in Advanced Solid Tumors
Twinpig Biolab, Inc.
Phase 1/2 Not yet recruiting
NCT07198321 2025-09-30
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Not yet recruiting
NCT07187284 2025-09-22
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
Zhongda Hospital
Phase 1/2 Not yet recruiting
NCT07175389 2025-09-16
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
West China Hospital
Phase 1/2 Not yet recruiting
NCT07153289 2025-09-03
ResCPa
University Hospital Tuebingen
Phase 1/2 Not yet recruiting
NCT07025850 2025-08-01
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
Fudan University
Phase 1/2 Not yet recruiting
NCT07075419 2025-07-20
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
West China Hospital
Phase 1/2 Not yet recruiting
NCT07042919 2025-06-29
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Northwestern University
Phase 1/2 Not yet recruiting
NCT05275374 2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2 Not yet recruiting
NCT06888648 2025-03-21
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Zhejiang University
Phase 1/2 Not yet recruiting
NCT06888674 2025-03-21
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
Zhejiang University
Phase 1/2 Not yet recruiting
NCT06871527 2025-03-12
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06866977 2025-03-10
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
Xiangya Hospital of Central South University
Phase 1/2 Not yet recruiting
NCT06860685 2025-03-06
Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Not yet recruiting
NCT04381130 2025-02-26
A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer
Everfront Biotech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06783153 2025-01-20
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Mansoura University
Phase 1/2 Not yet recruiting
NCT06746961 2024-12-24
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Not yet recruiting
NCT06584071 2024-12-16
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Biotheus Inc.
Phase 1/2 Not yet recruiting
NCT06662669 2024-10-29
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Not yet recruiting
NCT06641453 2024-10-16
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
Chinese PLA General Hospital
Phase 1/2 Not yet recruiting
NCT06592287 2024-09-19
The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 1/2 Not yet recruiting